

Express Mail Mailing Label N . EL953996882US

#18

SHEET 1 OF 5

FORM PTO - 1449				ATTORNEY DOCKET NO.: MEE-005			
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANTS: Adamis et al.			
				SERIAL NO.: 09/478,099			
				FILING DATE: January 5, 2000 GROUP: 1632			
U.S. PATENT DOCUMENTS							
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
Amz	A1	3,618,604	11/9/71	Ness et al.	128	260	
	A2	3,692,027	9/19/72	Ellinwood, Jr.	128	260	
	A3	3,961,628	6/8/76	Arnold	128	260	
	A4	3,963,025	6/15/76	Whitaker et al.	128	260	
	A5	4,003,379	1/18/77	Ellinwood, Jr.	128	260	
	A6	4,014,335	3/29/77	Arnold	128	260	
	A7	4,146,029	3/27/79	Ellinwood, Jr.	128	260	
	A8	4,177,256	12/4/79	Michaels et al.	424	22	
	A9	4,180,073	12/25/79	Michaels	128	260	
	A10	4,186,184	1/29/80	Zaffaroni	424	14	
	A11	4,203,442	5/20/80	Michaels	128	260	
	A12	4,281,654	8/4/81	Shell et al.	128	260	
	A13	4,360,019	11/23/82	Portner et al.	128	213 R	
	A14	4,475,916	10/9/84	Himmelstein	604	890	
	A15	4,544,371	10/1/85	Dormandy, Jr. et al.	604	891	
	A16	4,734,092	3/29/88	Millerd	604	67	
	A17	4,957,494	9/18/90	Wong et al.	604	892.1	
	A18	4,959,217	9/25/90	Sanders et al.	424	473	
	A19	5,061,242	10/29/91	Sampson	604	118	
	A20	5,236,689	8/17/93	Wong et al.	424	473	
↓	A21	5,266,332	11/30/93	Dong et al.	424	473	
Amz	A22	5,300,114	4/5/94	Gwon et al.	623	4	
EXAMINER Anne-marie Zalk				DATE CONSIDERED 4/8/03			

SHEET 2 OF 5

FORM PTO - 1449				ATTORNEY DOCKET NO.: MEE-005			
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANTS: Adamis et al.			
				SERIAL NO.: 09/478,099			
				FILING DATE: January 5, 2000 GROUP: 1632			
U.S. PATENT DOCUMENTS							
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
Amz	A23	5,348,746	9/20/94	Dong et al.	424	473	
	A24	5,366,454	11/22/94	Currie et al.	604	890.1	
	A25	5,378,475	1/3/95	Smith et al.	424	473	
	A26	5,391,381	2/21/95	Wong et al.	424	473	
	A27	5,443,508	8/22/95	Giampapa	623	11	
	A28	5,445,616	8/29/95	Kratoska et al.	604	141	
	A29	5,466,233	11/14/95	Weiner et al.	604	890.1	
	A30	5,475,096	12/12/95	Gold et al.	536	23.1	
	A31	5,582,981	12/10/96	Toole et al.	435	6	
	A32	5,607,418	3/4/97	Arzbaecher	604	891.1	
	A33	5,660,846	8/26/97	Cheikh	424	423	
	A34	5,725,493	3/10/98	Avery et al.	604	9	
	A35	5,736,152	4/7/98	Dunn	424	426	
	A36	5,756,291	5/26/98	Griffin et al.	435	6	
	A37	5,773,019	6/30/98	Ashton et al.	424	423	
	A38	5,797,898	8/25/98	Santini, Jr. et al.	604	890.1	
	A39	5,830,173	11/3/98	Avery et al.	604	9	
	A40	5,840,867	11/24/98	Toole et al.	536	23.1	
	A41	5,869,078	2/9/99	Baudino	424	423	
	A42	5,888,533	3/30/99	Dunn	424	423	
	A43	5,897,878	4/27/99	Dong et al.	424	473	
✓	A44	5,902,598	5/11/99	Chen et al.	424	423	
Amz	A45	5,993,414	11/30/99	Haller	604	93	
EXAMINER Anne-Marie Zalk				DATE CONSIDERED 4/8/03			

SHEET 3 OF 5

FORM PTO - 1449				ATTORNEY DOCKET NO.: MEE-005			
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANTS: Adamis <i>et al.</i>			
				SERIAL NO.: 09/478,099			
				FILING DATE: January 5, 2000 GROUP: 1632			
U.S. PATENT DOCUMENTS							
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
Am2	A46	6,001,386	12/14/99	Ashton et al.	424	423	
	A47	6,056,734	5/2/00	Jacobsen et al.	604	891.1	
	A48	6,074,673	6/13/00	Guillen	424	501	
	A49	6,120,789	9/19/00	Dunn	424	426	
	A50	6,123,861	9/26/00	Santini, Jr. et al.	216	2	
	A51	6,165,155	12/26/00	Jacobsen et al.	604	156	
	A52	6,203,523 B1	3/20/01	Haller et al.	604	93.01	
	A53	6,217,896 B1	4/17/01	Benjamin	424	427	
	A54	6,251,090 B1	6/26/01	Avcry et al.	604	9	
	A55	6,277,401 B1	8/21/01	Bello et al.	424	449	
	A56	6,283,949 B1	9/4/01	Roorda	604	288.02	
	A57	6,283,951 B1	9/4/01	Flaherty et al.	604	529	
	A58	6,306,420 B1	10/23/01	Cheikh	424	422	
	A59	6,312,393 B1	11/6/01	Abreu	600	558	
	A60	6,317,630 B1	11/13/01	Gross et al.	604	20	
	A61	6,319,245 B1	11/20/01	Berrigan	604	891.1	
	A62	6,331,313 B1	12/18/01	Wong et al.	424	427	
	A63	6,364,865 B1	4/2/02	Lavi et al.	604	411	
	A64	6,368,626 B1	4/9/02	Bhatt et al.	424	473	
	A65	6,368,629 B1	4/9/02	Watanabe et al.	424	482	
↓	A66	6,375,972 B1	4/23/02	Guo et al.	424	423	
Am2	A67	2002/0026176 A1	2/28/02	Varner et al.	604	891.1	
EXAMINER Anne-Marie Falk				DATE CONSIDERED 4/8/03			

SHEET 4 OF 5

FORM PTO - 1449				ATTORNEY DOCKET NO.: MEE-005					
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANTS: Adamis <i>et al.</i>					
				SERIAL NO.: 09/478,099					
				FILING DATE: January 5, 2000 GROUP: 1632					
U.S. PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
Am2	A68	6,413,540 B1	7/2/02	Yaacobi	424	427			
Am2	A69	6,416,777 B1	7/9/02	Yaacobi	424	428			
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
Am2	B1	86/00519 A	1/30/86	WO					Y
	B2	91/16869	11/14/91	WO					Y
	B3	93/21874	11/11/93	WO					Y
	B4	94/05257	3/17/94	WO					Y
	B5	94/13305	6/23/94	WO					Y
	B6	94/21314 A	9/29/94	WO					Y
	B7	00/38714	7/6/00	WO					Y
	B8	00/40089 A	7/13/00	WO					Y
	B9	01/28472 A1	4/26/01	WO					Y
	B10	01/28474 A1	4/26/01	WO					Y
	B11	01/30323	5/3/01	WO					Y
Am2	B12	01/80825 A	11/1/01	WO					Y
OTHER ART, JOURNAL ARTICLES, ETC.									
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)								
Am2	C1	Ambati, J. <i>et al.</i> "Diffusion of High Molecular Weight Compounds Through Sclera" <i>Invest. Ophthalmol. Vis. Sci.</i> (2000) 41: 1181-1185.							
Am2	C2	Canakis <i>et al.</i> "Characterization of Diffusion Across the Sclera Using FITC-Conjugates of Different Molecular Weights" <i>Invest. Ophthalmol. Vis. Sci.</i> (1997) Abstract 38: 683-B594.							
EXAMINER Anne-Marie Zalk				DATE CONSIDERED 4/8/03					

SHEET 5 OF 5

FORM PTO - 1449		ATTORNEY DOCKET NO.: MEE-005
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANTS: Adamis <i>et al.</i>
		SERIAL NO.: 09/478,099
		FILING DATE: January 5, 2000 GROUP: 1632
OTHER ART, JOURNAL ARTICLES, ETC.		
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
Ama	C3	Carrasquillo <i>et al.</i> "Controlled Delivery of Anti-VEGF Aptamer EYE001 with Poly(lactic-co-glycolic) Acid Microspheres" Poster presentation in 2002.
	C4	The Eyetech Study Group "Preclinical and Phase 1A Clinical Evaluation of an Anti-VEGF Pegylated Aptamer (EYE001) for the Treatment of Exudative Age-Related Macular Degeneration" <u>J. Retinal Vitreous Diseases</u> (2002) 22: 143-152
	C5	Jellinek <i>et al.</i> "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor" <u>Biochem.</u> (1994) 33: 10450-10456
	C6	Jo, B. <i>et al.</i> "Fabrication of Three-Dimensional Microfluidic Systems by Stacking Molded Polydimethylsiloxane (PDMS) Layers" <u>SPIE</u> (1999) 3877: 222-229.
Ama	C7	Ruckman <i>et al.</i> "2'-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF <sub>165</sub> )" <u>J. Biol. Chem.</u> (1998) 273: 20556-20567.
	C8	Santini, J. Jr. <i>et al.</i> "A Controlled-release Microchip" <u>Nature</u> (1999) 397: 335-338.
EXAMINER Anne-Marie Falk		DATE CONSIDERED 4/8/03